Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...

Fintel reports that on April 14, 2023, Mizuho initiated coverage of Axonics Modulation Technologies (NASDAQ:AXNX) with a Buy recommendation. As of April 6, 2023, the average one-year price target for ...

Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 5.09MM shares of Axonics Modulation Technologies Inc (AXNX). This represents 10.28% of the company. In ...

Axonics Modulation Technologies press release (NASDAQ:AXNX): Q1 GAAP EPS of -$0.19. Revenue of $70.7M (+46.0% Y/Y). Gross margin was 74.3% in 1Q23 compared to 68.7% in the prior year period. Operating ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Axonics Modulation Technologies Inc. (AXNX) on Tuesday reported a loss of $19.1 million in its first quarter. On a per-share basis, the Irvine, ...

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medtronic. The ...